ChromaDex® Receives ISO/IEC 17025:2005 Certification

IRVINE, Calif., Oct. 30, 2013 /PRNewswire/ -- ChromaDex Corp.^® (OTCQB: CDXC), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today that the ChromaDex analytics laboratory located in Boulder, Colorado has received the internationally recognized ISO (International Organization for Standardization) and IEC (International Electrotechnical Commission) 17025:2005 accreditation.

The ISO/IEC accreditation, which demonstrates technical competence for a defined testing scope and the operation of a laboratory quality management system, was granted by ACLASS, an ANSI-ASQ National Accreditation Board agency.

ISO/IEC 17025 is the international standard by which a laboratory's commitment to quality is evaluated. ChromaDex achieved this accreditation by demonstrating technical competence for the testing of dietary supplements. Competence requirements include testing performed using standard and/or non-standard methods and laboratory-developed methods. ISO 17025 not only considers the management and technical expertise, but also emphasizes continuous process improvement.

Commenting on the announcement, Frank Jaksch, ChromaDex Founder and CEO, states, "Receiving the ISO/IEC 17025 accreditation is a testament to our commitment for maintaining quality and excellence in our testing practices. The accreditation provides our customers with the utmost confidence that the accuracy of testing results produced by ChromaDex will carry a high degree of credibility and acceptance."

Mark Jost, Vice President of ChromaDex added, "ISO 17025 was identified as a key objective in our strategic planning process.  Achieving the accreditation was a result of hard work and dedication by the entire ChromaDex laboratory staff."

About ChromaDex^®:
ChromaDex® is an innovative natural products company that discovers, acquires, develops and commercializes proprietary-based ingredient technologies through its unique business model that utilizes its wholly owned synergistic business units, including ingredient technologies, natural product fine chemicals (known as "phytochemicals"), chemistry and analytical testing services, and product regulatory and safety consulting (as Spherix Consulting). The company provides seamless science-based solutions to the nutritional supplement, food and beverage, animal health, cosmetic and pharmaceutical industries. The ChromaDex ingredient technologies unit includes products backed with extensive scientific research and intellectual property. Its ingredient portfolio includes pTeroPure® pterostilbene; ProC3G™, a natural black rice containing cyanidin-3-glucoside; PURENERGY™, a caffeine-pTeroPure co-crystal; and NIAGEN™, its recently launched branded nicotinamide riboside, a novel next-generation B vitamin. To learn more about ChromaDex, visit www.chromadex.com.

Forward-Looking Statements:
Any statements that are not historical facts contained in this release are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to product and customer demand, market acceptance of our products, the effect of economic conditions both nationally and internationally, ability to protect our intellectual property rights, impact of any litigation or infringement actions brought against us, competition from other providers and products, risks in product development, our ability to raise capital to fund continuing operations, the ability to complete transactions, and other factors discussed from time to time in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.

ChromaDex Investor Contact:
The Del Mar Consulting Group, Inc.
Robert B. Prag, President
858-794-9500
[email protected]

or

Alex Partners, LLC
Scott Wilfong, President
425- 242-0891
[email protected]

ChromaDex Company Contact:
Laura Carney, Executive Assistant
949-419-0288
[email protected]

SOURCE ChromaDex Corp.